Shrestha, RupendraShrestha, ReenaKhadka, Ram BahadurGyawali, Rabin2026-02-262026-02-262021https://hdl.handle.net/20.500.14572/4935Rupendra Shrestha Department of Ophthalmology and Visual Sciences, Albert Einstein College of Medicine, New York, United States https://orcid.org/0000-0001-6804-6070 Reena Shrestha College of Medical Science and Teaching Hospital, Bharatpur, Chitwan, Nepal https://orcid.org/0000-0001-8412-282X Ram Bahadur Khadka Department of Medical Laboratory Technology, Crimson College of Technology, Butwal, Nepal https://orcid.org/0000-0002-2763-8261 Rabin Gyawali Department of Basic Sciences, Nepal Sanjivani Institute of Health Science, Dang, Nepal https://orcid.org/0000-0002-4928-5057Abstract: While there is absolutely no evidence to ensure recovered patients are either likely or unlikely to get reinfected. But studies in non-human primates indicate that reinfection of recovered patients is highly unlikely. It is also clear that primary immune responses or induced immunity to severe acute respiratory syndrome coronavirus 2 remain in circulation for several months and at least temporarily confer immunity to protect from reinfection. In addition, negative virus culture analysis of re-positive suggests that positive reverse transcriptase-polymerase chain reactions in recovered patients are more likely to be false-positive, or detection of genetic remnants of virus discharged from lesions of lungs or better sampling at the time of repeat analysis. However, emerging severe acute respiratory syndrome coronavirus 2 variants are likely to be causing the infections observed in some of the recovered patients.en-USCOVID-19immunityreactivationreinfectionArticle